Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.61 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30249073 | 1.00 | KMT2A (0.64) | KMT2AHTR2AIDO1TAAR1 | |
| SCHEMBL14655700 | 1.00 | KMT2A (0.64) | KMT2AHTR2AIDO1TAAR1 | |
| Hydrochloric Acid SCHEMBL28775228 | 0.98 | KMT2A (0.67) | KMT2AHTR2AIDO1 | |
| Iodide SCHEMBL28548071 | 0.98 | KMT2A (0.62) | KMT2AHTR2AIDO1TAAR1 | |
| Hydrochloric Acid SCHEMBL30559568 | 0.98 | KMT2A (0.67) | KMT2AHTR2AIDO1 | |
| SCHEMBL9638844 | 0.86 | IDO1 (0.57) | KMT2AIDO1TAAR1 | |
| SCHEMBL11946649 | 0.85 | IDO1 (0.52) | KMT2AHTR2AIDO1TAAR1 | |
| Hydrochloric Acid SCHEMBL5307530 | 0.84 | HTR2A (0.63) | HTR2ATAAR1 | |
| SCHEMBL878976 | 0.83 | IDO1 (0.53) | KMT2AIDO1TAAR1 | |
| SCHEMBL23929137 | 0.83 | KMT2A (0.55) | KMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101983-A1 | NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES | BRANDEIS UNIVERSITY (US) | 2025-05-15 | — | — | WO | claimed |
| CN-116970600-B | Nucleic acid extraction method based on magnetic resin | 南京诺唯赞生物科技股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119461707-A | Method and production system for extracting humic acid and fulvic acid in source water of drinking water | 南京大学 | 2025-02-18 | — | — | CN | claimed |
| CN-112748991-B | Method, apparatus and computer program product for backing up data | 伊姆西IP控股有限责任公司 | 2024-09-13 | — | — | CN | claimed |
| US-12045140-B2 | Live browsing of granular mailbox data | COMMVAULT SYSTEMS, INC. (US) | 2024-07-23 | — | — | US | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| US-11809517-B1 | Adaptive method of cleaning structural health monitoring data based on local outlier factor | SOUTHWEST JIAOTONG UNIVERSITY (CN) | 2023-11-07 | — | — | US | claimed |
| CN-116970600-A | Nucleic acid extraction method based on magnetic resin | 南京诺唯赞生物科技股份有限公司 | 2023-10-31 | — | — | CN | claimed |
| US-20230244572-A1 | LIVE BROWSING OF GRANULAR MAILBOX DATA | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2023-08-03 | — | — | US | claimed |
| CN-116489253-A | Network protocol analysis method and related components | 上海安恒智慧城市安全技术有限公司 | 2023-07-25 | — | — | CN | claimed |
| WO-2013014287-A2 | DEUTERIUM FREE, STABLE ISOTOPE LABELED 2-PHENYLETHYLAMINE HALLUCINOGENS AND/OR STIMULANTS, METHODS OF THEIR PREPARATION AND THEIR USE | CHIRON AS (NO) | 2013-01-31 | — | — | WO | claimed |
| EP-2551675-A1 | Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods fo their preparation and their use | Chiron AS (NO) | 2013-01-30 | — | — | EP | claimed |
| WO-2007094825-A2 | METAXALONE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2007-08-23 | — | — | WO | claimed |
| US-20050032781-A1 | Methods for administering active agents to CYP 2D6 sensitive patients | ALKERMES, INC. | 2005-02-10 | — | — | US | claimed |
| US-20040224960-A1 | Pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | claimed |
| US-20030144220-A1 | Use of CYP2D6 inhibitors in combination therapies | PFIZER INC. | 2003-07-31 | — | — | US | claimed |
| EP-1242058-A1 | USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES | Pfizer Products Inc. (US) | 2002-09-25 | — | — | EP | claimed |
| US-20020013372-A1 | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors | PFIZER PRODUCTS INC. | 2002-01-31 | — | — | US | claimed |
| EP-1134290-A2 | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors | Pfizer Products Inc. (US) | 2001-09-19 | — | — | EP | claimed |
| WO-2000059486-A2 | USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224960-A1 | Pharmaceutical compositions and methods for their use | CYP3A5, CYP3A7, CYP3A43 | KMT2A 3124/4885HTR2A 2025/4885IDO1 669/4885 |
| US-20030144220-A1 | Use of CYP2D6 inhibitors in combination therapies | CYP2D6, CYP2B6, CYP3A43 | KMT2A 1903/4885HTR2A 565/4885IDO1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.